{"doc_id": "33850184", "type of study": "Therapy", "title": "", "abstract": "Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.\nType 1 Interferons (IFNs) have been associated with positive effects on Coronaviruses.\nPrevious studies point towards the superior potency of IFN\u03b2 compared to IFN\u03b1 against viral infections.\nWe conducted a three-armed, individually-randomized, open-label, controlled trial of IFN\u03b21a and IFN\u03b21b, comparing them against each other and a control group.\nPatients were randomly assigned in a 1:1:1 ratio to IFN\u03b21a (subcutaneous injections of 12,000\u00a0IU on days 1, 3, 6), IFN\u03b21b (subcutaneous injections of 8,000,000\u00a0IU on days 1, 3, 6), or the control group.\nAll three arms orally received Lopinavir/Ritonavir (400\u00a0mg/100\u00a0mg twice a day for ten days) and a single dose of Hydroxychloroquine 400\u00a0mg on the first day.\nOur utilized primary outcome measure was Time To Clinical Improvement (TTCI) defined as the time from enrollment to discharge or a decline of two steps on the clinical seven-step ordinal scale, whichsoever came first.\nA total of 60 severely ill patients with positive RT-PCR and Chest CT scans underwent randomization (20 patients to each arm).\nIn the Intention-To-Treat population, IFN\u03b21a was associated with a significant difference against the control group, in the TTCI; (HR; 2.36, 95% CI 1.10-5.17, P-value\u2009=\u20090.031) while the IFN\u03b21b indicated no significant difference compared with the control; HR; 1.42, (95% CI 0.63-3.16, P-value\u2009=\u20090.395).\nThe median TTCI for both of the intervention groups was five days vs. seven days for the control group.\nThe mortality was numerically lower in both of the intervention groups (20% in the IFN\u03b21a group and 30% in the IFN\u03b21b group vs. 45% in the control group).\nThere were no significant differences between the three arms regarding the adverse events.\nIn patients with laboratory-confirmed SARS-CoV-2 infection, as compared with the base therapeutic regiment, the benefit of a significant reduction in TTCI was observed in the IFN\u03b21a arm.\nThis finding needs further confirmation in larger studies.\nTrial Registration Number: ClinicalTrials.gov, NCT04343768. (Submitted: 08/04/2020; First Online: 13/04/2020) (Registration Number: NCT04343768).\n", "Evidence Map": {"Enrollment": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 45}, {"term": "severely ill", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 26}, {"term": "positive RT-PCR", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 56}, {"term": "Chest CT scans", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 75}, {"term": "laboratory-confirmed SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 58}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Role of interferon therapy in severe COVID-19 : the COVIFERON randomized controlled trial .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 45}], "Intervention": [{"term": "interferon therapy", "negation": "affirmed", "UMLS": {}, "start": 8, "end": 26, "has_procedure": [{"text": "interferon therapy", "maps_to": "C0279030:interferon therapy", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Type 1 Interferons ( IFNs ) have been associated with positive effects on Coronaviruses .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Previous studies point towards the superior potency of IFN\u03b2 compared to IFN\u03b1 against viral infections .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We conducted a three-armed , individually-randomized , open-label , controlled trial of IFN\u03b21a and IFN\u03b21b , comparing them against each other and a control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "IFN\u03b21a", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 94, "has_relation": "N/A"}, {"term": "IFN\u03b21b", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 105, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients were randomly assigned in a 1:1:1 ratio to IFN\u03b21a ( subcutaneous injections of 12,000 IU on days 1 , 3, 6 ) , IFN\u03b21b ( subcutaneous injections of 8,000,000 IU on days 1 , 3, 6 ) , or the control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "IFN\u03b21a", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 58, "has_relation": "N/A"}, {"term": "IFN\u03b21b", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 125, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "All three arms orally received Lopinavir / Ritonavir ( 400 mg / 100 mg twice a day for ten days ) and a single dose of Hydroxychloroquine 400 mg on the first day .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Ritonavir", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 52, "has_chemical": [{"text": "ritonavir", "maps_to": "C0292818:ritonavir", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "Hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 137, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Our utilized primary outcome measure was Time To Clinical Improvement ( TTCI ) defined as the time from enrollment to discharge or a decline of two steps on the clinical seven-step ordinal scale , whichsoever came first .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Time To Clinical Improvement ( TTCI )", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 78}, {"term": "time from enrollment to discharge or a decline of two steps on the clinical seven-step ordinal", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 188}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "A total of 60 severely ill patients with positive RT-PCR and Chest CT scans underwent randomization ( 20 patients to each arm ) .", "Evidence Elements": {"Participant": [{"term": "severely ill", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 26}, {"term": "positive RT-PCR", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 56}, {"term": "Chest CT scans", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 75}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In the Intention-To-Treat population , IFN\u03b21a was associated with a significant difference against the control group , in the TTCI ; ( HR ; 2.36 , 95 % CI 1.10-5.17 , P-value = 0.031 ) while the IFN\u03b21b indicated no significant difference compared with the control ; HR ; 1.42 , ( 95 % CI 0.63-3.16 , P-value = 0.395 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "IFN\u03b21a", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 45, "has_relation": "N/A"}, {"term": "control", "negation": "negated", "UMLS": {}, "start": 103, "end": 110, "has_relation": "N/A"}, {"term": "TTCI", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 130, "has_relation": "N/A"}, {"term": "IFN\u03b21b", "negation": "affirmed", "UMLS": {}, "start": 195, "end": 201, "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 90}, {"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 90}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "IFN\u03b21a", "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}, {"term": "TTCI", "has_relation": "N/A"}], "Observation": "significant difference", "Outcome": "", "Count": ""}, {"Intervention": [{"term": "IFN\u03b21b", "has_relation": "N/A"}], "Observation": "significant difference", "Outcome": "", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "The median TTCI for both of the intervention groups was five days vs . seven days for the control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both of the intervention", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 44, "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 12, "end": 24}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 97, "has_relation": "N/A"}], "Outcome": [{"term": "median TTCI", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}], "Observation": [{"term": "five days", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 65}, {"term": "seven days", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 81}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "both of the intervention", "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 12, "end": 24}], "has_relation": "N/A"}, "Observation": "five days", "Outcome": "median TTCI", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "seven days", "Outcome": "median TTCI", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "The mortality was numerically lower in both of the intervention groups ( 20 % in the IFN\u03b21a group and 30 % in the IFN\u03b21b group vs . 45 % in the control group ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both of the intervention", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 63, "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 12, "end": 24}], "has_relation": "N/A"}, {"term": "IFN\u03b21a", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 91, "has_relation": "N/A"}, {"term": "IFN\u03b21b", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 120, "has_relation": "N/A"}], "Outcome": [{"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 13}], "Observation": [{"term": "numerically lower", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 35}, {"term": "20 %", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 77}, {"term": "30 %", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 106}, {"term": "45", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 134}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "both of the intervention", "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 12, "end": 24}], "has_relation": "N/A"}], "Observation": "numerically lower", "Outcome": "mortality", "Count": ""}, {"Intervention": {"term": "both of the intervention", "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 12, "end": 24}], "has_relation": "N/A"}, "Observation": "20 %", "Outcome": "mortality", "Count": ""}, {"Intervention": {"term": "IFN\u03b21a", "has_relation": "N/A"}, "Observation": "20 %", "Outcome": "mortality", "Count": ""}, {"Intervention": {"term": "IFN\u03b21b", "has_relation": "N/A"}, "Observation": "30 %", "Outcome": "mortality", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "There were no significant differences between the three arms regarding the adverse events .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the three arms", "negation": "negated", "UMLS": {}, "start": 38, "end": 60, "has_relation": "N/A"}], "Outcome": [{"term": "adverse events", "negation": "negated", "UMLS": {}, "start": 75, "end": 89}], "Observation": [{"term": "significant differences", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 37}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In patients with laboratory-confirmed SARS-CoV-2 infection , as compared with the base therapeutic regiment , the benefit of a significant reduction in TTCI was observed in the IFN\u03b21a arm .", "Evidence Elements": {"Participant": [{"term": "laboratory-confirmed SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 58}], "Intervention": [], "Outcome": [{"term": "TTCI", "negation": "affirmed", "UMLS": {}, "start": 152, "end": 156}], "Observation": [{"term": "significant reduction", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 148}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "This finding needs further confirmation in larger studies .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Trial Registration Number : ClinicalTrials.gov , NCT04343768 . ( Submitted : 08 / 04 / 2020 ; First Online : 13 / 04 / 2020 ) ( Registration Number : NCT04343768 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}